Evaluation of therapeutic effects of SGLT2 inhibitors in type 2 diabetes mellitus patients: a single centre, case series study

• At: Seville (Spain) (2022)
• Type: Poster
• Poster code: HPS-024
• By: TSENG, Hsiang-Yi ()
• Co-author(s): Ms Ching-Chih Huang, Pharmacist (Department of Pharmacy, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan China / Taichung City New Pharmacist Association, Taichung, Taiwan)
  Mr Pei-Liang Chen, Department of Pharmacy (Department of Pharmacy, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan China / Taichung City New Pharmacist Association, Taichung, Taiwan)
  Ms Pi-Chi Chi, Diabetes Mellitus Education Room (Diabetes Mellitus Education Room, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan China)
  Ms Hsiang-Yi Tseng, Department of Pharmacy (Department of Pharmacy, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan China / Taichung City New Pharmacist Association, Taichung, Taiwan)
  
• Abstract:

  Background information：
  According to the CREDENCE trial and the DAPA-CKD trial sodium-glucose cotransporter 2 (SGLT2) inhibitors are able to decrease the risk of worsening diabetic nephropathy. In the CREDENCE trial, Canagliflozin was used to lower the Urine Albumin-to-Creatinine Ratio (uACR), and from the results it only took six months to..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login